New Year New Vaccine? Will Novavax be too late or right in time? Is Novavax any good for Omicron?

#NovavaxUpdate #Novavax2022 #NovavaxFDA

Hi everyone, Happy new year!
Are we going to get a new type of COVID vaccine in 2022? Has Novavax stood by their words? Is Novavx any good for Omicron?
Let's find out!

If you appreciate my work, you can buy me a coffee. :)
https://www.buymeacoffee.com/dr2hong

Disclaimer:

This video is Dr. Hong’s interpretation and summary of publically available scientific information
This video is not intended to serve as any advice regarding the treatment, prevention, and diagnosis of any diseases
Dr. Hong has no connections and receives no monetary compensation from any pharmaceutical companies and government.
This video is for educational purposes only.

-------------------------------
To learn more:

Novavax COVID vaccine Where are you? Will you be too late?
https://youtu.be/YBWdCOwEP7s
-------------------------------
Source References:

Novavax Submits Final Data Packages to U.S. FDA as Prerequisite to Emergency Use Authorization Application Request for COVID-19 Vaccine
https://ir.novavax.com/2021-12-31-Novavax-Submits-Final-Data-Packages-to-U-S-FDA-as-Prerequisite-to-Emergency-Use-Authorization-Application-Request-for-COVID-19-Vaccine

Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies
https://ir.novavax.com/2021-12-22-Novavax-Announces-Initial-Omicron-Cross-Reactivity-Data-from-COVID-19-Vaccine-Booster-and-Adolescent-Studies

Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
https://www.medrxiv.org/content/10.1101/2021.12.23.21267374v1

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02717-3/fulltext#%20

Oxford Com-COV2 trial
https://comcovstudy.org.uk/about-com-cohttps://comcovstudy.org.uk/about-com-cov2v2

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults above or equals to 18 Years With a Pediatric Expansion in Adolescents (12 to less 18 Years) at Risk for SARS-CoV-2
https://clinicaltrials.gov/ct2/show/NCT04611802